The trading price of FibroGen Inc (NASDAQ:FGEN) closed lower on Tuesday, April 23, closing at $1.07, -6.14% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $20.28 and a 52-week low of $0.33. Over the past month, the stock has lost -58.53% in value.
FibroGen Inc, whose market valuation is $105.68 million at the time of this writing, is expected to release its quarterly earnings report May 06, 2024 – May 10, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.42 per share this quarter, however they have predicted annual earnings per share of -1.33 for current year and -0.44 for next year.
Analysts have forecast the company to bring in revenue of 36.67M for the current quarter, with the likely lows of 31.89M and highs of 41.44M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 155.41M.
On the technical side, indicators suggest FGEN has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Sell.
A quick review shows that FGEN’s price is currently -36.63% off the SMA20 and -44.12% off the SMA50. The RSI metric on the 14-day chart is currently showing 28.11, and weekly volatility stands at 12.23%. When measured over the past 30 days, the indicator reaches 15.63%. FibroGen Inc (NASDAQ:FGEN)’s beta value is currently sitting at 0.87, while the Average True Range indicator is currently displaying 0.21.
To see how FibroGen Inc stock has been performing in comparison to its peers in the industry, here are the numbers: FGEN stock’s performance was -6.14% in the latest trading, and -94.75% in the past year.
An evaluation of the daily trading volume of FibroGen Inc (NASDAQ:FGEN) indicates that the 3-month average is 2.81 million.
Currently, records show that 98.77 million of the company’s shares remain outstanding. The insiders hold 7.02% of outstanding shares, whereas institutions hold 71.28%. However, since the stock’s price has seen 20.73% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
